Chinese inhibitor drug candidate becomes first to enter phase
Time:2024-05-21 12:16:48 Source:businessViews(143)
Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312.
SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally.
The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations.
The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy.
Previous:The unstoppable duo of Emma Stone and Yorgos Lanthimos
Next:OpenAI pauses ChatGPT voice after Scarlett Johansson comparisons
You may also like
- Ohio judge to rule Monday on whether the state’s abortion ban stands
- Wellingtonians warned of bus, train disruptions on Monday
- Government warns against travel to Gaza, Israel border regions
- Malaysia considers hosting 'downsized' Commonwealth Games
- Jessica Biel CHOPS her long locks into a bob after book signing in Studio City
- Compulsory microchipping and desexing of pet cats after Lower Hutt council vote
- Christopher Luxon defends more funding for Ruapehu ski fields
- 'A disgrace': Families doing it tough after government cuts funding to food bank
- Kosovo prepares a new draft law on renting prison cells to Denmark after the first proposal failed